Medication effects on the gut microbiome in allo-HCT

Welles Robinson; E Michael Gertz; Tim F Greten; Eytan Ruppin

doi:10.1016/j.cell.2023.04.011

Medication effects on the gut microbiome in allo-HCT

Cell. 2023 Jun 8;186(12):2520-2523. doi: 10.1016/j.cell.2023.04.011. Epub 2023 Jun 8.

Authors

Welles Robinson¹, E Michael Gertz², Tim F Greten³, Eytan Ruppin⁴

Affiliations

¹ Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
² Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
³ Gastrointestinal Malignancies Section, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
⁴ Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: eytan.ruppin@nih.gov.

PMID: 37295398
DOI: 10.1016/j.cell.2023.04.011

Abstract

Decreased gut microbiome diversity has been associated with negative outcome in allogeneic hematopoietic stem cell transfer (HCT). A study published in this issue of Cell identifies associations between non-antibiotic drug administration, microbiome state transitions, and response to HCT, highlighting the potential impact of such drugs on microbiome and HCT outcome.

Published by Elsevier Inc.

Publication types

Comment

MeSH terms

Gastrointestinal Microbiome*
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Microbiota*